SAShivani Ahlawat

Shivani Ahlawat

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shivani Ahlawat has a total of 222 co-authors. Here are the top co-authors by number of shared publications:

  • Laura M. Fayad

    The Russel H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Johns Hopkins Medical Institutions, Baltimore, USA

    29 shared publications
  • Laura Marie Fayad

    The Johns Hopkins School of Medicine

    14 shared publications
  • Patrick Debs

    Department of Diagnostic Radiology, University of Maryland School of Medicine, Baltimore, MD, USA

    6 shared publications
  • Ali Ghasemi

    The Russel H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Johns Hopkins Medical Institutions , Baltimore (A.G., J.P., L.M.F., S.A.)

    5 shared publications
  • Jaishri O. Blakeley

    Department of Neurology, Neuro-Oncology, Johns Hopkins University School of Medicine, Baltimore, USA

    5 shared publications
  • Jan Fritz

    Department of Radiology, Grossman School of Medicine, New York University, New York, New York, United States

    5 shared publications

Latest Publications

  • Whole-Body MRI in Neurocutaneous Syndromes: Imaging Phenotypes, Surveillance Strategies, and Pitfalls

    by Zohaib Y. Ahmad, Laura M. Fayad, Shivani Ahlawat

    Neurocutaneous syndromes associated with peripheral nerve sheath tumors (PNSTs), particularly neurofibromatosis type 1 (NF1) and schwannomatosis (SWN), are characterized by variable tumor burden and multisystem involvement. Whole-body magnetic resonance imaging (WB-MRI) has emerged as an important imaging technique for screening, surveillance, lesion characterization, and treatment monitoring in both pediatric and adult populations. Updated molecular and imaging-based classification systems have further refined characterization of PNST phenotypes. In NF1, WB-MRI enables detection of internal tumor burden, longitudinal assessment of plexiform neurofibromas (PNs), and risk stratification for malignant peripheral nerve sheath tumor (MPNST) development. Diffusion-weighted imaging (DWI) with apparent diffusion coefficient (ADC) mapping improves differentiation between benign and malignant peripheral nerve sheath tumors with emerging data on premalignant precursor lesions called atypical neurofibromatous neoplasms of uncertain biologic potential (ANNUBP). In SWN, evolving diagnostic criteria and genotype-phenotype correlations have increased the importance of imaging in young patients presenting with solitary schwannoma or meningioma. WB-MRI can establish internal tumor burden, define disease extent, and support surveillance strategies across genetically defined SWN subtypes. This review summarizes current applications of WB-MRI in NF1 and SWN, including imaging phenotypes, surveillance strategies, advanced imaging biomarkers, treatment response assessment, and common technical and interpretive pitfalls.

  • Open Access

    Clinical and Imaging Phenotype of Schwannomatosis in Children, Adolescents and Young Adults

    by Shivani Ahlawat, Jaishri O. Blakeley, Laura M. Fayad, Krista S. Schatz, Stephanie M. Morris, Allan J. Belzberg, Bronwyn Slobogean, Carlos G. Romo

    Background/Objectives: To characterize the clinical and imaging phenotypes of schwannomatosis (SWN) in children, adolescents, and young adults (AYAs). Methods: This single-center retrospective cohort study included patients (age ≤ 25 years) with suspected SWN with archived magnetic resonance imaging (MRI) at Johns Hopkins between 2020–2026. Clinical characteristics, genetic testing results, and tumor imaging (including anatomic distribution), and treatment approaches were reviewed. Descriptive statistics were performed. Results: In total, thirty-eight patients with suspected SWN were identified (median age 20 years, range 6–25; 32% female). NF2-related SWN was the most common diagnosis (31/38, 82%; de novo: 24/31 (77%) and familial: 7/31 (23%)), followed by LZTR1-SWN (n = 1) and SWN-NOS/NEC (n = 2). A total of four patients (asymptomatic LZTR1 carriers (n = 2) and possible SWN (n = 2)) did not fulfill diagnostic criteria based on craniospinal and whole-body MRI. Familial NF2-SWN demonstrated a trend toward earlier presentation (median 5 vs. 8 years; p = 0.12). Visual manifestations occurred at a younger age than hearing loss (median 8 vs. 16 years; p = 0.053). Imaging burden was high (median 23 MRI/patient (range: 1–60). Bilateral vestibular schwannomas were nearly universal (30/31, 97%). Familial disease demonstrated a trend toward increased cranial meningiomas (86% vs. 54%; p = 0.20), while peripheral schwannomas (43% vs. 67%; p = 0.38) and ependymomas (14% vs. 42%; p = 0.37) were less frequent compared with de novo disease. Operative and non-operative management was documented in 65% (20/31) each. Conclusions: NF2-related SWN is the predominant subtype in a pediatric and AYA patient population and was associated with substantial early tumor burden at a tertiary specialty NF center.

  • Open Access

    New Approaches to Clinical Trials for Rare Diseases: Decentralized Trial Design for Neurofibromatosis Type 1 and Schwannomatosis

    by Vanessa L. Merker, Shivani Ahlawat, Robert A. Avery, Diana Bradford, Andrea M. Gross, Jennifer Janusz, Andrés J. Lessing, Linda Manth, Miranda L. McManus, Beverly Oberlander, et al.

    Background: In decentralized clinical trials, some or all activities occur outside of traditional sites, which may reduce time away from school/work and decrease participation burden for patients and their parents/caregivers. This methodology may improve recruitment and retention in studies, which is important for rare diseases like neurofibromatosis type 1 (NF1) and schwannomatosis (SWN). Published guidance exists for the general conduct of decentralized trials, but specific considerations for clinical trial design and endpoints in NF1/SWN have not yet been explored. Methods: The Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration is a group of researchers, clinicians, and people affected by NF1 and SWN whose shared goal is to advance clinical trial methodology for NF1/SWN. In December 2023, REiNS members met to discuss the opportunities and challenges of conducting NF1/SWN decentralized trials. Results: Endpoints that are promising for use in NF1/SWN decentralized trials include visual acuity (as tested by the computerized amblyopia treatment study HOTV testing algorithm); electronic versions of REiNS-recommended patient reported outcome measures; digital health technologies for functional outcomes; radiography and computed tomography scans for imaging outcomes; remote photography to assess cutaneous neurofibromas; “e-centralized” evaluations of neurocognitive functioning; and remote biomarkers collected with analyte stabilizing tubes and self-collection devices. Conclusions: Further research is necessary to validate endpoints for decentralized trials for NF1/SWN and evaluate their feasibility. However, trial designs that incorporate decentralized elements hold considerable promise for rare diseases like NF1/SWN where patients encounter significant barriers to traditional clinical trial participation.


  • Open Access

    RADS classification systems for bone tumors: current status and where do we go from here?

    by Vu Pham Thao Vy, Shivani Ahlawat, Hillary W. Garner, Jim S. Wu

    The assessment and management of bone tumors can be challenging as there are numerous neoplastic and non-neoplastic lesions. It can be difficult to underst


  • MRI-Based Synthetic CT Shows Promise as a Radiation-Free Alternative to Conventional CT in Orthopaedics

    by Henry Stewart, Aidan Watkins, Shivani Ahlawat, Laura M. Fayad, David L. Skaggs, Paul D. Sponseller

    ➢ Computed tomography (CT) remains the gold standard for bone imaging, but radiation risks, especially in children, are driving interest in alternatives. ➢ Magnetic resonance imaging (MRI)-based techniques are emerging as a radiation-free alternative to CT, using sequences such as zero echo time, ultrashort echo time, and 3-dimensional (3D) gradient recalled echo, along with deep learning-based synthetic CT. ➢ Zero echo time MRI stands out for its high-resolution and silent imaging, whereas 3D gradient recalled echo offers widespread availability and minimal requirements for implementation. ➢ Early studies have shown high agreement of all modalities with CT across multiple anatomical sites, supporting broader clinical use, especially in pediatrics, surgical planning, and cost-reduction efforts. ➢ Deep learning-based synthetic CT demonstrates strong potential given its ability to improve over time and to generate highly accurate CT-like images, although current applications are limited by existing training data.


  • Open Access

    Neurofibromatosis type 1-plexiform neurofibromas: Integrating treatment across pediatric and adult populations

    by Amy E Armstrong, Andrea M Gross, Laura J Klesse, Steven D Rhodes, Shivani Ahlawat, Verena Staedtke, Camilo A Molina, Angela C Hirbe

    Plexiform neurofibromas (PNs) are a hallmark of neurofibromatosis type 1 (NF1), affecting ∼50% of individuals with the condition. Originating from Schwann cells and other peripheral nerve sheath components, these tumors can cause significant morbidity, including functional impairment, diminished health-related quality of life, chronic pain, and malignant transformation. Managing NF1-PNs is challenging because of disease variability, differing growth rates, and age-related differences in clinical presentation and treatment tolerability. This review examines current therapeutic strategies, including surgery, medical therapies, and emerging treatments, emphasizing individualized care. Highlighted here is the need for age-specific treatment planning, particularly as disease progression, comorbidities, and side-effect profiles differ between pediatric and adult patients. Optimizing outcomes requires personalized surveillance and coordinated multidisciplinary management across all age groups. While MEK inhibitors (MEKi) provide therapeutic benefit, their long-term efficacy and safety, particularly in pediatric patients who may receive these agents for extended periods, warrant further investigation. Additionally, adult patients face unique comorbidities that may complicate therapy. Superficial PNs and potential MEK inhibitor resistance remain underexplored. Growing interest in combination therapies and adjuvant strategies may improve outcomes. Ongoing research is crucial to personalize treatment regimens, to identify effective combinations, and to refine surveillance protocols, ultimately enhancing long-term quality of life for individuals living with NF1-PN.


  • Imaging features and the role of image-guided biopsy for assessment of premalignant versus malignant peripheral nerve sheath tumors in neurofibromatosis type 1

    by Ali Ghasemi, Jaishri O Blakeley, Jenifer Pitman, Laura M Fayad, Carlos G Romo, Christine A Pratilas, Calixto-Hope G Lucas, Allan J Belzberg, Shivani Ahlawat

    Background: To compare the magnetic resonance imaging (MRI) features of histologically proven premalignant peripheral nerve sheath tumors (PNSTs) with high-grade malignant PNST and explore the utility of core needle biopsy (CNB) for confirming the diagnosis in people with neurofibromatosis type 1 (NF1). Methods: This study analyzed MRIs obtained from people with NF1 and histologically confirmed premalignant PNST (atypical neurofibromatous neoplasm of uncertain biologic potential [ANNUBP] or low-grade MPNST) or high-grade malignant PNST (MPNST). Demographic data, qualitative and quantitative imaging features (size and minimum apparent diffusion coefficient [ADCmin]), and diagnostic method (CNB or excision) were collected. Statistical analysis included Pearson’s chi-squared, Mann-Whitney U-tests, and Benjamini-Hochberg method. Results: A total of 41 tumors in 40 patients (20 females [median age: 35, range: 14-66] with high-grade MPNST (n = 30) or premalignant PNSTs (n = 11)) were included. The presence of intralesional necrosis, perilesional edema, and perilesional enhancement (P < .05); greater T2 heterogeneity (P = .001); a higher largest and average diameter (P = .014 and P = .018, respectively); and a lower ADCmin (P < .001) were associated with high-grade MPNST. When applying a binary classification scheme of premalignant PNST versus high-grade MPNST, CNB offered the correct diagnosis in 93% (27/29) of the PNSTs. Conclusion: The presence of intralesional necrosis, perilesional enhancement, and edema; higher T2 heterogeneity; large diameter (>10.5 cm) and average diameter (8.3 cm); and a lower ADCmin (<0.7 × 10−³ mm²/s) are associated with high-grade MPNST in people with NF1. As efforts continue to more precisely define transitional tumors molecularly, histologically, and clinically versus high-grade MPNST, these data contribute to the MRI diagnostic distinctions.

  • How I Do It: MRI of the Bone with Marrow-specific Sequences

    by Shivani Ahlawat, Ali Ghasemi, Laura M. Fayad

    A marrow-specific MRI protocol including noncontrast T1-weighted fast spin-echo imaging, chemical shift imaging, and diffusion-weighted imaging is useful for distinguishing normal bone marrow and red marrow reconversion from bone marrow disorders.